Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights
March 01, 2018 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 8th, 2018 at 1:30...
Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
February 07, 2018 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that H. Ward Wolff has been appointed to the Sunesis Board of Directors....
Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017
December 05, 2017 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
-Company announces vecabrutinib as generic name for SNS-062- -Event on December 9 in Atlanta, GA with Slide Webcast- SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Sunesis...
Sunesis Pharmaceuticals Announces Change in Leadership
December 04, 2017 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
- Daniel Swisher Resigns as CEO Effective End of 2017; to Remain with Sunesis as a Strategic Advisor - - Board Member Dayton Misfeldt Appointed Interim CEO Effective January 2018; Board Starting...
Sunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development
November 30, 2017 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the appointment of William Quinn as Chief Financial Officer and Senior Vice...
Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights
November 02, 2017 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the third quarter ended September 30, 2017. Loss from...
Sunesis to Host Conference Call on November 2nd to Discuss Third Quarter 2017 Financial Results and Recent Highlights
October 27, 2017 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, November 2, 2017 at 2:00...
Sunesis Announces Pricing of $20 Million Offering of Securities
October 25, 2017 08:54 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of underwritten public offerings of (i) 7,500,000 shares of its...
Sunesis Announces Proposed Public Offering of Common Stock, Preferred Stock and Warrants
October 24, 2017 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it intends to offer and sell, subject to market and other conditions,...
Sunesis to Present at Upcoming Investor Conferences
August 31, 2017 07:00 ET
|
Sunesis Pharmaceuticals Inc
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the company will present at two upcoming investor conferences. ...